Hyperforin and its analogues inhibit CYP3A4 enzyme activity

Phytochemistry

Volumn 67, Issue 23, 2006, Pages 2550-2560

  Lee, Ju young ^a   Duke, Rujee K ^b   Tran, Van H ^a   Hook, James M ^c   Duke, Colin C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Acylphloroglucinols; Furoadhyperforin; Furohyperforin; Hyperforin; MS and CYP3A4 enzyme; NMR; St. John's wort

Indexed keywords

BICYCLO COMPOUND; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE; HYPERFORIN; PHLOROGLUCINOL; TERPENE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; HYPERICUM; ISOLATION AND PURIFICATION; METABOLISM;

BICYCLO COMPOUNDS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYPERICUM; MOLECULAR STRUCTURE; PHLOROGLUCINOL; TERPENES;

EID: 33750696607     PISSN: 00319422     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phytochem.2006.09.018     Document Type: Article

References (50)

1. Arold G., Donath F., Maurer A., Diefenbach K., Bauer S., Henneicke-von Zepelin H.H., Friede M., and Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract. Planta Med. 71 4 (2005) 331-337
2. Blumenthal M. Herb sales down 7.4 percent in mainstream market. HerbalGram 66 (2005) 63
3. Braun S., Kalinowski H.O., and Berger S. 150 and More Basic NMR Experiments (1998), Wiley-VCH, Weinheim
4. Breidenbach T., Hoffmann M.W., Becker T., Schlitt H., and Klempnauer J. Drug interaction of St. John's wort with cyclosporine. Lancet 335 (2000) 1912
5. Butterweck V., Christoffel V., Nahrstedt A., Petereit F., Spengler B., and Winterhoff H. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparation in behavioral models. Life Sci. 73 (2003) 627-639
6. Calapai G., Crupi A., Firenzuoli F., Inferrero G., Squadrito F., Parisi A., De Sarro G., and Caputi A. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry 34 2 (2001) 45-49
7. Cantoni L., Rozio M., Mangolini A., Hauri L., and Caccia S. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol. Sci. 75 1 (2003) 25-30
8. Chatterjee S.S., Bhattacharya S.K., Wonnemann M., Singer A., and Müller W.E. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci. 63 6 (1998) 499-510
9. Chauret N., Tremblay N., Lackman R.L., Gauthier J.Y., Silva J.M., Marois J., Yergey J.A., and Nicoll-Griffith D.A. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsome using a selective fluorescent probe. Anal. Biochem. 276 (1999) 215-226
10. Cott J.M. In vitro receptor binding and enzyme inhibition to Hypericum perforatum extract. Pharmacopsychiatry 30 Suppl. 2 (1997) 108-112
11. Cui Y., Ang C.Y.W., Beger R.D., Heinze T.M., Hu L., and Leakey J. In vitro metabolism of hyperforin in rat liver microsomal systems. Drug Metab. Dispos. 32 (2004) 28-34
12. Di Carlo G., Borrelli F., Ernst E., and Izzo A.A. St. John's wort: Prozac from the plant kingdom. Trends Pharmacol. Sci. 22 (2001) 292-297
13. Di Marco A., Marcucci I., Verdirame M., Perez J., Sanchez M., Pelaez F., Chaudhary A., and Laufer R. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metab. Dispos. 33 (2005) 349-358
14. Ernst E. Second thoughts about safety of St. John's wort. Lancet 354 (1999) 2014-2016
15. Feißt C., Albert D., Verotta L., and Werz O. Evaluation of hyperforin analogues for inhibition of 5-lipoxygenase. Med. Chem. 1 3 (2005) 287-291
16. Fuzzati N., Gabetta B., Strepponi I., and Villa F. High-performance liquid chromatography-electrospray ionisation mass spectrometry and multiple mass spectrometry studies of hyperforin degradation products. J. Chromatogr. A 926 (2001) 187-198
17. Guengerich F.P. Role of cytochrome P450 enzymes in drug-drug interactions. Drug-Drug Interactions: Scientific and Regulatory Perspectives (1997), Academic Press, San Diego pp. 7-35
18. Hall S., Wang Z., Huang S.M., Hamman M.A., Vasavada N., Adigun A.Q., Hilligoss J.K., Miller M., and Gorski C. The interaction between St. John's wort and an oral contraceptive. Clin. Pharmacol. Ther. 74 (2003) 525-535
19. Josey E.S., and Tackett R.L. St. John's wort: a new alternative for depression. Int. J. Clin. Pharmacol. Ther. 37 (1999) 111-119
20. Keller J.-H., Karas M., Müller W.E., Volmer D.A., Eckert G.P., Tawab M.A., Blume H.H., Dingermann T., and Schubert-Zsilavecz M. Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry. Anal. Chem. 75 (2003) 6084-6088
21. Komoroski B.J., Zhang S., Cai H., Hutzler M., Frye R., Tracy T.S., Storm S.C., Lehmann T., Ang C.Y.W., Cui Y., and Venkataramanan R. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos. 32 5 (2004) 512-518
22. Lawvere S., and Mahoney M.C. St. John's wort. Complement. Altern. Med. 72 11 (2005) 2249-2254
23. Lecrubier Y., Clerc G., Didi R., and Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry 159 8 (2002) 1361-1366
24. Luo G., Lin J., Fiske W.D., Dai R., Yang T.J., Kim S., Sinz M., Lecluyse E., Solon E., Brennan J.M., Benedek I.H., Jolley S., Gilbert D., Wang L., Lee F.W., and Gan L.-S. Concurrent induction and mechanism-based inactivation of CYP3A4 by an l-valinamide derivative. Drug Metab. Dispos. 31 9 (2003) 1170-1175
25. Madabushi R., Frank B., Drewelow B., Derendorf H., and Butterweck V. Hyperforin in St. John's wort drug interactions. Eur. J. Clin. Pharmacol. 62 (2006) 225-233
26. Mai I., Kruger H., Budde K., Johne A., Brockmolleer J., Neumayer H.H., and Roots I. Hazardous pharmacokinetic interaction of St. John's wort (Hypericum perforatum) with the immunosuppressant cyclosporine. Int. J. Clin. Pharmacol. Ther. 38 10 (2000) 500-502
27. Maisenbacher P., and Kovar K.A. Adhyperforin: a homologue of hyperforin from Hypericum perforatum. Planta Med. 58 (1992) 291-293
28. Mannel M. Drug interactions with St. John's wort: mechanism and clinical implications. Drug Safety 27 11 (2004) 773-797
29. Markowitz J.S., Donovan J.L., De Vane C.L., Taylor R.M., Ruan Y., Wang J.-S., and Chavin K.D. Effects of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290 11 (2003) 1500-1504
30. Mueller S.C., Majcher-Peszynska J., Uehleke B., Klammt S., Mundkowski R.G., Miekisch W., Sievers H., Bauer S., Frank B., Kundt G., and Drewelow B. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol. 62 (2006) 29-36
31. Müller W.E. Current St. John's wort research from mode of action to clinical efficacy. Pharmacol. Res. 47 (2003) 101-109
32. Nahrstedt A., and Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 30S (1997) 129-134
33. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther. 294 (2000) 88-95
34. Orth H.C.J., Rentel C., and Schmidt P.C. Isolation, purity analysis and stability of hyperforin as a standard material form Hypericum perforatum L. J. Pharm. Pharmacol. 51 (1999) 193-200
35. Piscitelli S.C., Brustein A.H., Chairr D., Alfaro R.M., and Falloon J. Indinavir concentrations and St. John's wort. Lancet 355 (2000) 547-548
36. Riley R.J., Parker A.J., Trigg S., and Manners C.N. Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharmceut. Res. 18 5 (2001) 652-655
37. Roby C.A., Anderson G.D., Kantor E., Dryer D.A., and Burstein A.H. St. John's wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther. 67 (2000) 451-457
38. Schrader E. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomised, controlled study in mild-moderated depression. Int. Clin. Psychopharmcol. 15 (2000) 61-68
39. Schulz V. Safety of St. John's wort extract compared to synthetic antidepressants. Phytomedicine 13 (2006) 199-204
40. Shadle C.R., Lee Y., Majumdar A.K., Petty K.J., Gargano C., Bradstreet T.E., Evans J.K., and Blum R.A. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J. Clin. Pharmcol. 44 3 (2004) 215-223
41. Verotta L., Appendino G., Bello E., Jakupovic J., and Bombardelli E. Furohyperforin, a prenylated phloroglucinol from St. John's wort (Hypericum perforatum). J. Nat. Prod. 62 (1999) 770-772
42. Verotta L., Appendino G., Jakupovic J., and Bombardelli E. Hyperforin analogues from St. John's wort (Hypericum perforatum). J. Nat. Prod. 63 (2000) 412-415
43. Verotta L., Appendino G., Belloro E., Bianchi F., Sterner O., Lovati M., and Bombardelli E. Synthesis and biological evaluation of hyperforin analogues. Part I. Modification of the enolized cyclohexanedione moiety. J. Nat. Prod. 65 4 (2002) 433-438
44. Verotta L. Hypericum perforatum, a source of neuroactive lead structures. Curr. Top. Med. Chem. 3 (2003) 187-201
45. Vugdelija S., Vajs V., Trifunovic S., Djokovic D., and Milosavljevic S. A new heterocyclization product of adhyperforin from Hypericum perforatum (St. John's wort). Molecules 5 (2000) M158
46. Wang Z., Ashraf-Khorassani M., and Taylor L.T. Air/light-free hyphenated extraction/analysis system: supercritical fluid extraction on-line coupled with liquid chromatography-UV absorbance/electrospray mass spectrometry for the determination of hyperforin and its degradation products in Hypericum perforatum. Anal. Chem. 76 22 (2004) 6771-6776
47. Wang Z., Gorski C., Hamman M., Huang S.M., Lesko L.J., and Hall S.D. The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther. 70 (2001) 317-326
48. Woelk H. Comparison of St. John's wort and imipramine for treating depression: randomised controlled trial. Brit. Med. J. 321 7260 (2000) 536-539
49. Wolfender J.L., Verotta L., Belvisi L., Fuzzati N., and Hostettmann K. Structural investigations of isomeric oxidised forms of hyperforin by HPLC-NMR and HPLC-MS. Phytochem. Anal. 14 (2003) 290-297
50. Zhang J.G., Dehal S.S., Ho T., Johnson D.M., and Wong J. Human cytochrome P450 induction and inhibition potential of clevidipine and its primary metabolite H152/81. Drug Metab. Dispos. 34 5 (2006) 734-737